Adlai Nortye to Participate in Upcoming Investor Conferences

Core Insights - Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing innovative cancer therapies [2] - The company will participate in two upcoming investor conferences, including the Evercore Healthcare Conference and the Oppenheimer Annual Healthcare Life Sciences Conference [1][2] Company Overview - Adlai Nortye operates with a dual R&D presence in the U.S. and China, aiming to build a robust pipeline of drug candidates [2] - The company focuses on two key areas: next-generation cancer immunotherapies and RAS-targeting therapies [2] - Key drug candidates include AN8025, a tri-functional fusion protein, AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC [2]